Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
-
- STATUS
- Recruiting
-
- End date
- Jun 24, 2023
-
- participants needed
- 20
-
- sponsor
- City of Hope Medical Center
Summary
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and more to measure value and quality in cancer care. This trial may show whether at-home monitoring programs can improve the care of patients after hospital discharge from surgery.
Description
PRIMARY OBJECTIVES:
I. To assess the feasibility and acceptability of remote perioperative monitoring in solid tumor cancer patients scheduled for gastrointestinal (GI), genitourinary (GU), gynecological (GYN) cancer surgery.
II. To explore patterns, trajectory, and changes in physiologic health parameter outcomes (weight, temperature, oxygen saturation, heart rate, blood pressure, daily steps) and patient-reported outcomes (PROs) (symptoms, quality of life [QOL]) from pre-surgery to the post-discharge period.
III. To explore the relationship between changes in physiologic health parameter outcomes/PROs and surgical outcomes (postoperative complications, readmissions).
IV. To explore changes in physiologic health parameters and PROs by open surgery versus minimally invasive (laparoscopic or robotic) surgery.
- OUTLINE
Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
After completion of study, patients are followed up for 2 months.
Details
| Condition | Stage I Uterine Corpus Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage 0 Gastric Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Cancer/Tumors, Malignant Genitourinary System Neoplasm, Stage IV Ovarian Cancer, Stage IIC Prostate Cancer AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Stage I Bladder Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage 0a Bladder Cancer AJCC v8, Neoplasms, Stage IVC Colorectal Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, malignant tumor, Stage IA2 Cervical Cancer AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, primary malignant neoplasm, Pathologic Stage IIIA Gastric Cancer AJCC v8, malignancies, Stage II Renal Cell Cancer AJCC v8, primary cancer, Stage III Uterine Corpus Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Ewing's Family Tumors, Stage IIIA1 Ovarian Cancer AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Stage IIB Prostate Cancer AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, iia1, Stage IC Ovarian Cancer AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Hepatobiliary Neoplasm, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage I Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage 0 Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Gynecologic Cancer, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, malignant tumors, Stage IIIB Colorectal Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, gastrointestinal cancers, Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Malignant Digestive System Neoplasm, Stage IIIA Cervical Cancer AJCC v8, cancers, Stage IB1 Cervical Cancer AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Malignant Female Reproductive System Neoplasm, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8, iia2, Stage III Ovarian Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Stage IB Ovarian Cancer AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Stage II Bladder Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Stage I Prostate Cancer AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Genitourinary Cancer, Stage IV Renal Cell Cancer AJCC v8, Cancer (Pediatric), Stage I Colorectal Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Cancer, Stage IV Bladder Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, gastrointestinal cancer, Stage IIA Cervical Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, malignancy, Stage III Prostate Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 |
|---|---|
| Treatment | questionnaire administration, Patient monitoring |
| Clinical Study Identifier | NCT04501913 |
| Sponsor | City of Hope Medical Center |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer